<DOC>
	<DOCNO>NCT00240877</DOCNO>
	<brief_summary>To assess safety vaccine healthy adult prior release trivalent vaccine ( FluMist ) .</brief_summary>
	<brief_title>Study Evaluate Safety Monovalent Vaccine New 6:2 Reassortant Healthy Adults ( AV024 )</brief_title>
	<detailed_description>The primary study objective ass safety monovalent vaccine new 6:2 reassortant healthy adult prior release trivalent vaccine ( FluMist ) . Safety demonstrate similar fever rate ( oral temperature ≥101°F ) vaccine placebo recipient .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1864 year age ( yet reach 65th birthday ) ; In good health ; Available telephone ; Ability understand comply requirement protocol ; Signed informed consent . Any condition , age , inactivate influenza vaccine indicate , include : chronic disorder pulmonary cardiovascular system , include asthma ; chronic metabolic disease ( include diabetes mellitus ) renal dysfunction , hemoglobinopathy require regular medical followup hospitalization proceed year ; Acute febrile ( &gt; 100.0°F oral ) illness clinically significant respiratory illness within 14 day prior enrollment ; Hypersensitivity egg egg protein ; Signs symptom immunosuppressive immune deficiency disease , include HIV infection , ongoing immunosuppressive therapy ; immunosuppressed individual living household ; Participation another investigational trial within one month prior enrollment expect enrollment another investigational trial study ; Any condition opinion investigator , might interfere vaccine evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>